Endocrine Abstracts

Pembrolizumab is a monoclonal antibody (ab) that exerts antineoplastic effects by inhibiting the immunoevasive effects PD-1 grants cancer cells. It’s used to treat several forms of cancer, including melanoma and non-small cell lung cancer. Despite the promise pembrolizumab has demonstrated, it has been associated with immune-related adverse events. In this report, we describe the first case of both thyroiditis and hypophysitis occurring during active pembrolizumab t...